Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma

Anna Maria Rachiglio, Riziero Esposito Abate, Alessandra Sacco, Raffaella Pasquale, Francesca Fenizia, Matilde Lambiase, Alessandro Morabito, Agnese Montanino, Gaetano Rocco, Carmen Romano, Anna Nappi, Rosario Vincenzo Iaffaioli, Fabiana Tatangelo, Gerardo Botti, Fortunato Ciardiello, Monica R. Maiello, Antonella De Luca, Nicola Normanno

Research output: Contribution to journalArticle

Abstract

The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing (NGS) can assess hundred mutations starting from a low DNA input. We performed NGS analysis of ctDNA from 44 patients with metastatic non-small-cell lung carcinoma (NSCLC) and 35 patients with metastatic colorectal carcinoma (CRC). NGS detected EGFR mutations in 17/22 plasma samples from EGFR-mutant NSCLC patients (sensitivity 77.3%). The concordance rate between tissue and plasma in NSCLC was much lower for other mutations such as KRAS that, based on the allelic frequency and the fraction of neoplastic cells, were likely to be sub-clonal. NGS also identified EGFR mutations in plasma samples from two patients with EGFR wild type tumor tissue. Both mutations were confirmed by droplet digital PCR (ddPCR) in both plasma and tissue samples. In CRC, the sensitivity of the NGS plasma analysis for RAS mutations was 100% (6/6) in patients that had not resection of the primary tumor before blood drawing, and 46.2% (6/13) in patients with primary tumor resected before enrollment. Our study showed that NGS is a suitable method for plasma testing. However, its clinical sensitivity is significantly affected by the presence of the primary tumor and by the heterogeneity of driver mutations.

Original languageEnglish
Pages (from-to)66595-66605
Number of pages11
JournalOncotarget
Volume7
Issue number41
DOIs
Publication statusPublished - 2016

Fingerprint

Colon
Carcinoma
Biopsy
Lung
Mutation
Neoplasms
Non-Small Cell Lung Carcinoma
Colorectal Neoplasms
DNA
DNA Fingerprinting
Polymerase Chain Reaction

Keywords

  • Colon cancer
  • Driver mutations
  • Liquid biopsy
  • Lung cancer
  • Targeted sequencing

ASJC Scopus subject areas

  • Oncology

Cite this

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. / Rachiglio, Anna Maria; Abate, Riziero Esposito; Sacco, Alessandra; Pasquale, Raffaella; Fenizia, Francesca; Lambiase, Matilde; Morabito, Alessandro; Montanino, Agnese; Rocco, Gaetano; Romano, Carmen; Nappi, Anna; Iaffaioli, Rosario Vincenzo; Tatangelo, Fabiana; Botti, Gerardo; Ciardiello, Fortunato; Maiello, Monica R.; De Luca, Antonella; Normanno, Nicola.

In: Oncotarget, Vol. 7, No. 41, 2016, p. 66595-66605.

Research output: Contribution to journalArticle

Rachiglio, Anna Maria ; Abate, Riziero Esposito ; Sacco, Alessandra ; Pasquale, Raffaella ; Fenizia, Francesca ; Lambiase, Matilde ; Morabito, Alessandro ; Montanino, Agnese ; Rocco, Gaetano ; Romano, Carmen ; Nappi, Anna ; Iaffaioli, Rosario Vincenzo ; Tatangelo, Fabiana ; Botti, Gerardo ; Ciardiello, Fortunato ; Maiello, Monica R. ; De Luca, Antonella ; Normanno, Nicola. / Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 41. pp. 66595-66605.
@article{eed7f782d34647ffb06b8d0cf5ce5d5d,
title = "Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma",
abstract = "The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing (NGS) can assess hundred mutations starting from a low DNA input. We performed NGS analysis of ctDNA from 44 patients with metastatic non-small-cell lung carcinoma (NSCLC) and 35 patients with metastatic colorectal carcinoma (CRC). NGS detected EGFR mutations in 17/22 plasma samples from EGFR-mutant NSCLC patients (sensitivity 77.3{\%}). The concordance rate between tissue and plasma in NSCLC was much lower for other mutations such as KRAS that, based on the allelic frequency and the fraction of neoplastic cells, were likely to be sub-clonal. NGS also identified EGFR mutations in plasma samples from two patients with EGFR wild type tumor tissue. Both mutations were confirmed by droplet digital PCR (ddPCR) in both plasma and tissue samples. In CRC, the sensitivity of the NGS plasma analysis for RAS mutations was 100{\%} (6/6) in patients that had not resection of the primary tumor before blood drawing, and 46.2{\%} (6/13) in patients with primary tumor resected before enrollment. Our study showed that NGS is a suitable method for plasma testing. However, its clinical sensitivity is significantly affected by the presence of the primary tumor and by the heterogeneity of driver mutations.",
keywords = "Colon cancer, Driver mutations, Liquid biopsy, Lung cancer, Targeted sequencing",
author = "Rachiglio, {Anna Maria} and Abate, {Riziero Esposito} and Alessandra Sacco and Raffaella Pasquale and Francesca Fenizia and Matilde Lambiase and Alessandro Morabito and Agnese Montanino and Gaetano Rocco and Carmen Romano and Anna Nappi and Iaffaioli, {Rosario Vincenzo} and Fabiana Tatangelo and Gerardo Botti and Fortunato Ciardiello and Maiello, {Monica R.} and {De Luca}, Antonella and Nicola Normanno",
year = "2016",
doi = "10.18632/oncotarget.10704",
language = "English",
volume = "7",
pages = "66595--66605",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "41",

}

TY - JOUR

T1 - Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma

AU - Rachiglio, Anna Maria

AU - Abate, Riziero Esposito

AU - Sacco, Alessandra

AU - Pasquale, Raffaella

AU - Fenizia, Francesca

AU - Lambiase, Matilde

AU - Morabito, Alessandro

AU - Montanino, Agnese

AU - Rocco, Gaetano

AU - Romano, Carmen

AU - Nappi, Anna

AU - Iaffaioli, Rosario Vincenzo

AU - Tatangelo, Fabiana

AU - Botti, Gerardo

AU - Ciardiello, Fortunato

AU - Maiello, Monica R.

AU - De Luca, Antonella

AU - Normanno, Nicola

PY - 2016

Y1 - 2016

N2 - The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing (NGS) can assess hundred mutations starting from a low DNA input. We performed NGS analysis of ctDNA from 44 patients with metastatic non-small-cell lung carcinoma (NSCLC) and 35 patients with metastatic colorectal carcinoma (CRC). NGS detected EGFR mutations in 17/22 plasma samples from EGFR-mutant NSCLC patients (sensitivity 77.3%). The concordance rate between tissue and plasma in NSCLC was much lower for other mutations such as KRAS that, based on the allelic frequency and the fraction of neoplastic cells, were likely to be sub-clonal. NGS also identified EGFR mutations in plasma samples from two patients with EGFR wild type tumor tissue. Both mutations were confirmed by droplet digital PCR (ddPCR) in both plasma and tissue samples. In CRC, the sensitivity of the NGS plasma analysis for RAS mutations was 100% (6/6) in patients that had not resection of the primary tumor before blood drawing, and 46.2% (6/13) in patients with primary tumor resected before enrollment. Our study showed that NGS is a suitable method for plasma testing. However, its clinical sensitivity is significantly affected by the presence of the primary tumor and by the heterogeneity of driver mutations.

AB - The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing (NGS) can assess hundred mutations starting from a low DNA input. We performed NGS analysis of ctDNA from 44 patients with metastatic non-small-cell lung carcinoma (NSCLC) and 35 patients with metastatic colorectal carcinoma (CRC). NGS detected EGFR mutations in 17/22 plasma samples from EGFR-mutant NSCLC patients (sensitivity 77.3%). The concordance rate between tissue and plasma in NSCLC was much lower for other mutations such as KRAS that, based on the allelic frequency and the fraction of neoplastic cells, were likely to be sub-clonal. NGS also identified EGFR mutations in plasma samples from two patients with EGFR wild type tumor tissue. Both mutations were confirmed by droplet digital PCR (ddPCR) in both plasma and tissue samples. In CRC, the sensitivity of the NGS plasma analysis for RAS mutations was 100% (6/6) in patients that had not resection of the primary tumor before blood drawing, and 46.2% (6/13) in patients with primary tumor resected before enrollment. Our study showed that NGS is a suitable method for plasma testing. However, its clinical sensitivity is significantly affected by the presence of the primary tumor and by the heterogeneity of driver mutations.

KW - Colon cancer

KW - Driver mutations

KW - Liquid biopsy

KW - Lung cancer

KW - Targeted sequencing

UR - http://www.scopus.com/inward/record.url?scp=84994000791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994000791&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10704

DO - 10.18632/oncotarget.10704

M3 - Article

AN - SCOPUS:84994000791

VL - 7

SP - 66595

EP - 66605

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 41

ER -